Stock SUVEN SUVEN LIFE SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Suven Life Sciences Limited NSE India S.E.

Equities

SUVEN

INE495B01038

Market Closed - NSE India S.E.
Other stock markets
 09:03:24 2024-04-25 am EDT 		5-day change 1st Jan Change
113.6 INR +1.02% Intraday chart for Suven Life Sciences Limited +1.56% +40.68%
Apr. 15 Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA CI
Feb. 06 Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA
CI
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA
CI
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024
CI
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant
PU
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy
CI
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3
PU
Suven Pharma Appoints New Board and Management Team
CI
Suven Pharma Appoints Sudhir Kumar Singh as CEO
CI
Transcript : Suven Life Sciences Limited, Q1 2024 Earnings Call, Aug 10, 2023
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
CI
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.
PU
Suven Life Sciences : Form MGT-7 FY 2022-23
PU
Suven Life Sciences : Annual Report FY 2022-23 (Book)
PU
Suven Life Sciences : Annual Report 2022-2023
PU
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting
AQ
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)
PU
Suven Life Sciences : June 01, 2023Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA
PU
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SUVEN Stock
  4. SUVEN Stock
  5. News Suven Life Sciences Limited